PharmaBlock Group

11/15/2021

PharmaBlock is committed to using our innovation, voice, reach and expertise to support more for the entire community.

Thanks to JJ Conde, Executive Director Process R&D at PharmaBlock USA,our actions and voice made a positive impact within the world.

11/10/2021

11/09/2021

Due to its high selectivity, mild reaction conditions, and tunable catalysis properties, biocatalysis has become one of the greenest technologies in the pharmaceutical industry.

PharmaBlock holds an in-house enzyme stock, complemented with many well-testified commercial enzymes. Our biocatalysis capability can facilitate the customized process and production of APIs and intermediates. Providing better, faster, and lower-cost biocatalysis solution to our customers is our goal.

In this article, Dr. Larry Y Wang discussed the biocatalysis technology process development in the pharmaceutical industry and shares the experience with cases.

Read more:
https://www.pharmablock.com/index.php/resource.html

10/12/2021

PharmaBlock A forward-looking CDMO

10/12/2021

【Visit Our Virtual Booth】On-site or online, we keep staying connected with our global clients. Come visit our new Virtual Booth, join us in any time zone and save time while keeping updated with the latest from PharmaBlock!

Offline meetings will continue and more schedules will be announced in the coming weeks.

There are a lot of reasons to get on board with us!

Click the link below to meet us now！

Home, 南京药石科技股份有限公司

10/12/2021

We are excited to announce that PharmaBlock has been listed in the“Forbes Asia's Best Under A Billion 2021".The list identifies companies with long-term excellence across a variety of measures. From a universe of 20,000 publicly traded companies in the Asia-Pacific region with annual revenue above $10 million and below $1 billion, only 200 companies were selected. PharmaBlock keeps steady growth even under the epidemic, and its ever-changing mission is to provide better products and services through innovation of chemistry and low carbon technology in R&D and manufacturing, and eventually to support partners to accelerate drug discovery and development, and move the new molecules into the market at full speed.